

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia: a population-based matched cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050285
Article Type:	Original research
Date Submitted by the Author:	15-Feb-2021
Complete List of Authors:	Jensen, Karen; Aarhus University Hospital, Department of Paediatrics and Adolescent Medicine Klug Albertsen, Birgitte; Aarhus University Hospital, Department of Pediatrics and Adolescent Medicine Schrøder, Henrik; Aarhus University Hospital, Department of Paediatrics and Adolescent Medicine Zalounina Falborg, Alina; Aarhus University, Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health Schmiegelow, Kjeld; Copenhagen University Hospital, Department of Paediatrics and Adolescent Medicine; University of Copenhagen, Institute of Clinical Medicine, Faculty of Health and Medical Sciences Rosthøj, Steen ; Aalborg University Hospital, Department of Paediatrics and Adolescent Medicine Callesen, Michael Thude; Odense University Hospital, Hans Christian Andersen Children's Hospital Vedsted, Peter; Aarhus Universitet, Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health
Keywords:	EPIDEMIOLOGY, Leukaemia < HAEMATOLOGY, Paediatric oncology < PAEDIATRICS, PRIMARY CARE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia: a population-based matched cohort study

Karen Schow Jensen<sup>1</sup>, Birgitte Klug Albertsen<sup>1</sup>, Henrik Schrøder<sup>1</sup>, Alina Zalounina Falborg<sup>2</sup>, Kjeld Schmiegelow<sup>3,4</sup>, Steen Rosthøj<sup>5</sup>, Michael Thude Callesen<sup>6</sup> and Peter Vedsted<sup>2</sup>

<sup>1</sup>Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.

<sup>2</sup>Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.

<sup>3</sup>Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark.

<sup>4</sup>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

<sup>5</sup>Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark.

<sup>6</sup>Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.

1  
2  
3  
4  
5  
6  
7 Corresponding author: Karen Schow Jensen, Department of Paediatrics and Adolescent Medicine,  
8  
9 Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus N, Denmark.

10  
11  
12 E-mail: [kascje@rm.dk](mailto:kascje@rm.dk)  
13  
14  
15

16  
17  
18 Abstract: 293 words  
19

20  
21 Main text: 1731 words, one text box, one table and four figures  
22

23  
24  
25 Supplementary data: Two tables  
26  
27

## 28 Abstract

29  
30  
31  
32

33 **Objectives** To investigate health care utilisation including both primary and secondary health care six  
34  
35 months before the diagnosis of a relapse or a second malignant neoplasm (SMN) in survivors of  
36  
37 childhood acute lymphoblastic leukaemia (ALL).  
38  
39  
40  
41

42 **Design and setting** A Danish population-based matched cohort study linking multiple nationwide  
43  
44 registries.  
45  
46  
47

48 **Participants** A total of 622 childhood ALL 2.5-year event-free survivors diagnosed between 1994 and  
49  
50  
51 2015. Cases were survivors developing a relapse or an SMN and references were survivors still in  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 first remission. Each case was matched with five references on age, sex, treatment protocol and risk  
4  
5  
6 group.

7  
8  
9 **Primary outcome measures** Consultations in general practice and hospital the last six months before  
10  
11  
12 relapse or SMN. Cases and references were compared with monthly incidence rate ratios (IRR) from  
13  
14  
15 negative binomial regression models.

16  
17  
18 **Results** Of the 622 childhood ALL survivors, 60 (9.6%) developed a relapse or an SMN. Health care  
19  
20  
21 utilisation in general practice increased among cases the last month before the event compared with  
22  
23  
24 references with an IRR of 2.71 (95% CI 1.71-4.28). Data showed a bimodal structure with a  
25  
26  
27 significantly increased number of visits four, five and six months before the event. Hospital health  
28  
29  
30 care utilisation increased two months before the event in cases with an IRR of 5.01 (95% CI 3.78-  
31  
32  
33 6.63) the last month before the event and an IRR of 1.94 (95% CI 1.32-2.85) the second-last month  
34  
35  
36 comparing cases and references.

37  
38  
39 **Conclusions** Survivors of childhood ALL developing a relapse or an SMN have a short period of  
40  
41  
42 increased health care utilisation before diagnosis. At hospital, this might be explained by pre-  
43  
44  
45 diagnostic examinations. In general practice, data suggest a bimodal structure with children later  
46  
47  
48 developing a relapse having more contacts also half a year before the relapse, which suggests that  
49  
50  
51 there could be early warnings.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Keywords

Leukaemia, Paediatric oncology, Epidemiology, Primary care

## Strengths and limitations of this study

- The first study to investigate healthcare utilisation before a relapse or an SMN in survivors of childhood ALL.
- Use of complete nationwide registries with nearly no loss to follow-up linked on an individual level ensured that the study was population-based thus limiting selection bias.
- Outcome data are collected routinely and uniformly in the Danish healthcare system and potential misclassification is thus expected to be non-differential.
- A relatively small case group, leading to low statistical precision.
- Unmeasured confounding could be present.

## Introduction

Five-year survival from childhood acute lymphoblastic leukaemia (ALL) now exceeds 90% with an event-free five-year survival of around 85%.<sup>1</sup> With increased survival rates, more survivors need

1  
2  
3 scheduled surveillance programmes for detection of possible late effects as well as screening for  
4  
5  
6 relapse of ALL or second malignant neoplasm (SMN). ALL survivors are known to have more  
7  
8  
9 chronic conditions (late effects) than their general population peers and to have increased use of  
10  
11  
12 both primary and secondary health care services after end of treatment.<sup>2-14</sup> Studies examining the  
13  
14  
15 occurrence of late effects have contributed with important knowledge to follow-up programmes.  
16  
17  
18 However, to the best of our knowledge, no studies have investigated the use of health care before a  
19  
20  
21 relapse or an SMN in survivors of childhood ALL.  
22  
23  
24  
25  
26  
27

28 Studies of health care use before a primary diagnosis of childhood ALL have revealed increased  
29  
30  
31 health care use 2-3 months before the diagnosis, thus reflecting a short period of symptoms.<sup>15, 16</sup>  
32  
33

34 Adolescents and young adults are found to have a longer interval with increased primary health care  
35  
36  
37 use for 5-6 months before primary diagnosis.<sup>17</sup> Earlier studies indicate that the increased primary  
38  
39  
40 health care use could have a bimodal structure with the first peak 10-12 months before the primary  
41  
42  
43 diagnosis.<sup>15</sup>  
44  
45  
46  
47  
48

49 Health care utilisation may reflect both the duration of symptoms before the diagnosis is established  
50  
51  
52 and the sectorial distribution of utilised care associated with these symptoms. Considerable focus is  
53  
54  
55 devoted to follow-up strategies for this group, and knowledge about the duration of increased health  
56  
57  
58  
59  
60



1  
2  
3 care use and the sectorial distribution of patients' help-seeking behaviour is therefore highly  
4  
5  
6 relevant. To address this knowledge gap, we aimed to analyse health care utilisation in general  
7  
8  
9 practice and hospital during the six-month period preceding a relapse or an SMN in survivors of  
10  
11  
12 childhood ALL.  
13

## 14 15 16 17 18 19 **Methods**

### 20 21 22 23 **Study design and setting**

24  
25  
26  
27 This study is a nationwide, population-based, matched cohort study linking information from several  
28  
29  
30 Danish registries. We followed the RECORD guidelines for reporting of studies conducted using  
31  
32  
33 observational, routinely collected health data.<sup>18</sup> (Supplementary Table S1).  
34  
35  
36  
37  
38  
39

40 In Denmark, the health care system is tax-financed and available to all residents (population 5.8  
41  
42 million). All Danish citizens are assigned a unique identifier, the Civil Personal Registration (CPR)  
43  
44  
45 number. The CPR number follows every resident from birth to death; data extracted from Danish  
46  
47  
48 public registries were linked on an individual level using the CPR number.  
49  
50  
51  
52  
53  
54

### 55 56 57 **Participants**

1  
2  
3 Eligible subjects were patients (1.0-17.9 years) diagnosed with non-infant Philadelphia chromosome-  
4  
5  
6 negative B-cell precursor or T-lineage ALL between 1994 and 2015, identified in the Danish part of  
7  
8  
9 the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL database. Cases were  
10  
11  
12 defined as childhood ALL survivors having a relapse or an SMN as the first event 2.5 years or more  
13  
14  
15 after primary diagnosis and before December 2017. Cases were matched 1:5 with childhood ALL  
16  
17  
18 survivors still in first remission with the same sex, age group (under 10 years or 10 years or more),  
19  
20  
21 NOPHO treatment protocol (ALL1992, ALL2000 or ALL2008) and risk group (high-risk or non-high  
22  
23  
24 risk) (see flow chart, Figure 1). Matching was based on incidence density sampling using the STATA  
25  
26  
27 command, sttocc. Due to the population-based design, the study sample size was determined by the  
28  
29  
30 number of cases in the area during the study period and no sample size calculation was performed.  
31  
32  
33  
34  
35  
36

### 37 Data sources and variables

38  
39  
40 Data were extracted from national registries (Text box) and hosted by Statistics Denmark. Authors  
41  
42  
43 had access to a de-identified data output. Data on health care utilisation were extracted for the  
44  
45  
46  
47 period 1 January 1997 to 31 December 2017.  
48  
49  
50  
51  
52

53 **Text box.** Data sources and variables  
54  
55  
56  
57  
58  
59  
60

	Registries	Variables
<b>Exposures</b>	NOPHO ALL Registry* <sup>1, 19</sup>	Relapse of ALL
		First remission
	Danish Cancer Registry† <sup>20</sup>	Second malignant neoplasm
<b>Outcomes</b>		
Primary health care	National Health Insurance Service Register‡ <sup>21</sup>	Daytime contacts to general practice:
		Daytime face-to-face contacts
		Email consultations
		Daytime telephone consultations
		Daytime home visits
		Out-of-hours contacts:
		Out-of-hours face-to-face contacts
		Out-of-hours telephone consultations
		Out-of-hours home visits
		Diagnostic procedures in general practice:
		Blood test
		Urine test
		Streptococcus throat test
Pulmonary functions test		
Electrocardiogram		
Secondary health care	Danish National Patient Registry§ <sup>22</sup>	Contacts to public and private hospitals:
		Inpatient hospitalisations
		Outpatient visits

Covariates	Danish Civil Registration System <sup>23</sup>	Sex
		Age
		Vital status
		Immigration
		Emigration
	NOPHO ALL Registry	Diagnosis of childhood ALL
		Treatment protocol (ALL1992, ALL2000 or ALL2008)
		Risk group (high-risk or non-high risk)
		Immunophenotype (B-precursor ALL or T-ALL)

\*NOPHO ALL Registry, Nordic Society of Paediatric Haematology and Oncology ALL Registry. The registry holds data on all children aged 1.0-14.9 years in Denmark diagnosed with ALL since 1992. From 2008 and onwards, the ALL Registry was extended to include children and adolescents aged 1.0-17.9 years.

†The Danish Cancer Registry holds information on all new cases of cancer in Denmark.

‡The National Health Insurance Service Register holds information on all contacts to general practice in Denmark. The following contacts were excluded: preventive health examination of children, vaccinations, screening for cervical cancer and pregnancy care. For a complete list of codes, see Supplementary data Table S2.

§The Danish National Patient Registry holds information on all contacts to public and private hospitals. The following contacts were excluded: visits to the accident and emergency department.

## Statistical methods

The index date was the date of event (relapse or SMN) for cases. The corresponding index date for references was defined as the date with the same interval from the primary diagnosis as for the

1  
2  
3 case. For all included individuals, follow-up started no earlier than 2.5 years after diagnosis to  
4  
5  
6 ensure that treatment had ended and remission reached. Health care utilisation was assessed from  
7  
8  
9 six months before the index date/event.  
10

11  
12  
13  
14  
15 The monthly rates for primary health care contacts (daytime contacts, out-of-hours contacts and  
16  
17  
18 diagnostic procedures) and hospital contacts (inpatient hospitalisations and hospital outpatient  
19  
20  
21 contact) were calculated as crude estimates for each of the six months preceding the index date.  
22

23  
24  
25 Negative binominal regression models were used to calculate incidence rate ratios (IRRs) to  
26  
27  
28 compare monthly rates of contacts between cases and references. Cluster robust variance  
29  
30  
31 estimation was applied to account for possible cluster effects at patient level. This was relevant as  
32  
33  
34 measurements on the same person were repeated monthly.  
35

36  
37  
38  
39  
40 Estimates of IRRs were adjusted for sex, age and time since diagnosis. To adjust for age and time  
41  
42  
43 since diagnosis, we used restricted cubic splines with six knots to allow for a non-linear relationship.  
44

45  
46 Furthermore, we performed analyses restricted to cases developing a relapse and to their  
47  
48  
49 references. All estimates are presented with 95% confidence intervals (CIs). All tests were two-sided  
50  
51  
52 and a P-value  $\leq 0.05$  was considered statistically significant. Data were analysed using the statistical  
53  
54  
55 software Stata 16.1 (StataCorp LLC, TX, USA).  
56  
57  
58  
59  
60

## Patient and public involvement

The study included no patient and public involvement.

## Results

### Patient characteristics

The study included 60 cases and 295 references; 49 (81.7%) of the 60 cases suffered a relapse and 11 (18.3%) an SMN (Table 1). In two cases, there were fewer than five matching references.

Table 1. Characteristics of the study population

Characteristic	Cases*	References†
	N = 60	N = 295
Sex, n (%)		
Male	38 (63.3)	190 (64.4)
Female	22 (36.7)	105 (35.6)
Median age at index date‡, (IQR)	11.3 (8.4-16.1)	11.1 (7.7-15.7)
Age group at index date, n (%)		
Age < 10 years	21 (35.0)	130 (44.1)

Age $\geq$ 10 years	39 (65.0)	165 (55.9)
Treatment protocol, n (%)		
NOPHO ALL1992	24 (40.0)	120 (40.7)
NOPHO ALL2000	22 (36.7)	105 (35.6)
NOPHO ALL2008	14 (23.3)	70 (23.7)
Cell line, n (%)		
B-precursor ALL	55 (91.7)	253 (85.8)
T-ALL	5 (8.3)	42 (14.2)
Risk group, n (%)		
Non-high-risk	46 (76.7)	230 (78.0)
High-risk	14 (23.3)	65 (22.0)
Median time from diagnosis to index date (years, IQI)	3.8 (3.2-5.1)	3.8 (3.2-5.1)
Type of event, n (%)		
Relapse	49 (81.7)	-
SMN	11 (18.3)	-

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

‡Index date, the date of event for cases and the corresponding date for references.

SMN, second malignant neoplasm; IQI, interquartile interval; NOPHO, Nordic Society of Paediatric Haematology and Oncology; ALL, acute lymphoblastic leukaemia.

## Health care utilisation

1  
2  
3 We found a mean of 0.73 (95% CI: 0.53-1.02) daytime general practice visits during the month  
4  
5  
6 before the event in cases corresponding to an IRR of 2.71 (95% CI: 1.71-4.28). For the month before  
7  
8  
9 the event, we found an IRR of 8.12 (95% CI 3.01-21.86) for general practice out-of-hours contacts  
10  
11  
12 and an IRR of 5.89 (95% CI 2.44-14.21) for diagnostic procedures in general practice (Figure 2). For  
13  
14  
15 daytime general practice visits, data suggest a possible bimodal structure with increased IRRs  
16  
17  
18 during 4-6 months before the event.  
19  
20  
21  
22  
23  
24

25 For cases, hospital utilisation was 3.42 (95% CI 2.83-4.12) contacts in the last month before the  
26  
27 event compared to 0.72 (95% CI 0.61-0.85) contacts for references, corresponding to an IRR of 5.01  
28  
29 (95% CI 3.78-6.63) the month before the event. For the second-last month before the event, we  
30  
31 found an IRR of 1.94 (95% CI 1.32-2.85) (Figure 3).  
32  
33  
34  
35  
36  
37  
38  
39

40 In analyses restricted to cases developing a relapse, hospital utilisation also increased two months  
41  
42 before the event (significantly increased only one month before the event). In general practice, data  
43  
44 continued to suggest a bimodal structure (Figure 4).  
45  
46  
47  
48  
49  
50  
51

## 52 Discussion

53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The present national, population-based matched cohort study shows that utilisation of general  
4  
5  
6 practice and hospital services increased significantly two months before the diagnosis of a relapse or  
7  
8  
9 an SMN compared to references still in first remission. This indicates that the diagnoses were made  
10  
11  
12 within two months. Our data showed a bimodal structure for daytime consultations in general  
13  
14  
15 practice in general and for cases developing a relapse in particular, with increased utilisation 5-6  
16  
17  
18 months before relapse. This indicates that there could be early warnings. The increased use of  
19  
20  
21 hospital health care services the last month before relapse is most likely explained by the diagnostic  
22  
23  
24 workup.  
25  
26  
27  
28  
29  
30

## 31 Strengths and limitations

32  
33  
34

35 The population-based design with use of nationwide registries linked on an individual level is a  
36  
37  
38 strength. This ensured optimal completeness of data and follow-up. However, a relapse diagnosis is  
39  
40  
41 not registered in the Danish Cancer Registry. Therefore, data on relapses were collected from the  
42  
43  
44 NOPHO ALL registry.<sup>1, 19</sup> The NOPHO ALL registry is a very robust data source as it is updated  
45  
46  
47 regularly by research nurses and paediatric oncologists. Nevertheless, the registry might not contain  
48  
49  
50 data on all relapses that occur after patients leave a paediatric department. Children with a relapse  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 that was unregistered would belong to the reference group, which could lead to bias towards  
4  
5  
6 underestimating relapse frequency and the differences in use of health care services.  
7  
8  
9

10  
11  
12 Electronic outcome data are collected routinely and uniformly in the Danish healthcare system. Data  
13  
14  
15 were collected for remuneration and not for the purpose of the present study. Potential  
16  
17  
18 misclassification of outcomes is expected to be equally distributed among cases and references, and  
19  
20  
21 any such misclassification is expected to be non-differential.<sup>24</sup>  
22  
23  
24  
25  
26  
27

28 The relatively small case group in our study is a limitation, leading to a low statistical precision with  
29  
30  
31 broad confidence intervals.  
32  
33  
34  
35  
36

37 We compared periods with the same interval from diagnosis in cases and references as previous  
38  
39  
40 research has shown that time since diagnosis affects utilisation of health care.<sup>2, 5, 8, 9</sup> We made an  
41  
42  
43 effort to reduce confounding by age, gender, calendar period and treatment regime by matching  
44  
45  
46 cases with references. We were not able to adjust for sociodemographic factors and unmeasured  
47  
48  
49 confounding could thus be present. We expect potential bias to be negligible, and we believe that  
50  
51  
52 our findings can be generalised to other countries with comparable healthcare systems.  
53  
54  
55  
56  
57  
58  
59  
60

## Comparison with existing literature

Previous studies on health care utilisation in ALL survivors have found increased use of primary and secondary health care after end of treatment.<sup>2-14</sup> However, previous studies did not evaluate health care use before a relapse or an SMN. Studies on health care utilisation before primary ALL diagnosis in childhood found increased use of health care 2-3 months before the primary diagnosis;<sup>15, 16</sup> and based on these findings, we expected a short duration of increased health care use. Furthermore, a bimodal structure for general practice health care use before the primary diagnosis is reported, but with the first peak 10-12 months before diagnosis.<sup>15</sup>

A recent study examining use of health care before a cancer recurrence or an SMN in adult cancer survivors reported increased use of health care up to a year before diagnosis among patients diagnosed with a wide range of solid tumours.<sup>25</sup> Based on knowledge on health care use before a primary cancer, it is expected that patients with solid tumours have a longer interval of increased health care utilisation.<sup>15, 17</sup>

## Conclusions

Survivors of childhood ALL developing a relapse or an SMN when in remission had a higher use of general practice and hospital health care services compared with matched references, 1-2 months

1  
2  
3 before the event. There was a possible bimodal structure for daytime visits to general practice with  
4  
5  
6 increased visits also 4-6 months before the event. As health care utilisation may be seen as a proxy  
7  
8  
9 for morbidity, this indicates that there could be early warnings. To the best of our knowledge, this is  
10  
11  
12 the first study to investigate use of health care before a relapse or an SMN in survivors of childhood  
13  
14  
15 ALL in remission, and further research is needed.  
16  
17  
18  
19  
20  
21

## 22 Figure legends

### 26 Figure 1 Flow diagram of the study population

28 Children with relapse/SMN and matched references in first remission.

29 \*Matching on age group, sex, risk group and treatment protocol.

30 †The number in brackets is the number of unique persons – the same child can serve as a control  
31 more than once.

32 Ph-negative BCR-ALL or T-ALL, Philadelphia chromosome-negative B-cell precursor or T-lineage  
33 acute lymphoblastic leukaemia; CPR number, civil personal registration number; HSCT in CR1,  
34 haematopoietic stem cell transplantation in first complete remission; SMN, second malignant  
35 neoplasm.  
36  
37  
38  
39  
40  
41  
42

### 43 Figure 2 General practice health care utilisation

44  
45 General practice utilisation by months before event for cases\* (n=60) compared with references†  
46 (n=295). (A) Daytime. (B) Out-of-hours. (C) Diagnostic procedures.

47  
48 Top panel: Contacts/diagnostic procedure mean rates per month presented as crude rates. Bottom  
49 panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent  
50 95% confidence intervals.  
51  
52

53 \*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 †References, survivors of childhood ALL still in first remission matched on age, sex, treatment  
4 protocol and risk group.

5  
6 ALL, acute lymphoblastic leukaemia; SMN, Second malignant neoplasm.  
7  
8  
9  
10  
11

## 12 Figure 3 Hospital health care utilization

13  
14  
15 Hospital health care utilisation by months before event for cases\* (n=60) compared with references†  
16 (n=295).

17  
18 Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate  
19 ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence  
20 intervals.  
21

22 \*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

23 †References, survivors of childhood ALL still in first remission matched on age, sex, treatment  
24 protocol and risk group.  
25

26 ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.  
27  
28  
29  
30

## 31 Figure 4 Health care utilisation

32  
33 Health care utilisation by months before event for cases (n=49) compared with references\* (n=243).

34 Cases are survivors of childhood ALL developing a relapse as the first event (cases developing an  
35 SMN are excluded in this analysis).  
36

37  
38 Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate  
39 ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence  
40 intervals.  
41

42 \*References, survivors of childhood ALL still in first remission matched on age, sex, treatment  
43 protocol and risk group.  
44

45 ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.  
46  
47  
48  
49  
50  
51

## 52 Acknowledgments

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The authors wish to thank Kaare Rud Flarup for his assistance with data management.  
4  
5  
6  
7  
8  
9

## 10 Footnotes

11  
12  
13

14  
15 **Contributors:** KJ designed the study, analysed and interpreted data and wrote the manuscript; BA  
16  
17 interpreted data and edited the manuscript; HS designed the study and edited the manuscript; AF  
18  
19 analysed and interpreted data and edited the manuscript; KS interpreted data and edited the  
20  
21 manuscript; SR interpreted data and edited the manuscript; MC interpreted data and edited the  
22  
23 manuscript; PV designed the study, interpreted data and edited the manuscript. All authors approved  
24  
25  
26  
27  
28  
29  
30 the final manuscript.  
31  
32  
33  
34  
35

36 **Funding:** This work was supported by a grant from the Danish Cancer Society (Kræftens  
37  
38 Bekæmpelse). Grant number R124-A7831-15-S2. The funders had no role in the design and  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

54  
55 **Competing interests:** Birgitte Klug Albertsen declares the following: sponsor for the investigator  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 Amgen (2020) and Medscape (2020); Educational grant from Servier (2020). The remaining authors  
4  
5  
6 declare that they have no competing interests.  
7  
8  
9  
10  
11

12 **Patient consent for publication:** Not required.  
13  
14  
15  
16  
17

18 **Ethical approval:** This study was approved by the Danish Data Protection Agency (ID 277). Medical  
19  
20  
21 ethical approval was not required according to Danish law.  
22  
23  
24  
25  
26  
27

28 **Data sharing statement:** According to the data agreement with the data provider, we are not allowed  
29  
30  
31 to share our data. Data are stored and maintained electronically at Statistics Denmark.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References


1. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. *Leukemia* 2018;32(3):606-15. doi: 10.1038/leu.2017.265 [published Online First: 2017/08/19]
2. de Fine Licht S, Rugbjerg K, Gudmundsdottir T, et al. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors. *PLoS medicine* 2017;14(5):e1002296. doi: 10.1371/journal.pmed.1002296 [published Online First: 2017/05/10]
3. Font-Gonzalez A, Feijen E, Geskus RB, et al. Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage study. *Cancer medicine* 2017;6(5):1123-34. doi: 10.1002/cam4.1057 [published Online First: 2017/04/06]
4. Sieswerda E, Font-Gonzalez A, Reitsma JB, et al. High Hospitalization Rates in Survivors of Childhood Cancer: A Longitudinal Follow-Up Study Using Medical Record Linkage. *PLoS One* 2016;11(7):e0159518. doi: 10.1371/journal.pone.0159518 [published Online First: 2016/07/21]
5. Sorensen GV, Winther JF, de Fine Licht S, et al. Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries. *Journal of the National Cancer Institute* 2019;111(9):943-51. doi: 10.1093/jnci/djz016 [published Online First: 2019/02/13]
6. Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. *The Lancet Haematology* 2019;6(6):e306-e16. doi: 10.1016/s2352-3026(19)30050-x [published Online First: 2019/05/13]
7. Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet (London, England)* 2017;390(10112):2569-82. doi: 10.1016/s0140-6736(17)31610-0 [published Online First: 2017/09/12]
8. Heins MJ, Lorenzi MF, Korevaar JC, et al. Non-oncology physician visits after diagnosis of cancer in adolescents and young adults. *Journal of cancer survivorship : research and practice* 2016;10(4):783-8. doi: 10.1007/s11764-016-0523-x [published Online First: 2016/02/15]
9. Heins MJ, Lorenzi MF, Korevaar JC, et al. Non-oncology physician visits after diagnosis of cancer in children. *BMC family practice* 2016;17:60. doi: 10.1186/s12875-016-0462-7 [published Online First: 2016/06/02]
10. Rebholz CE, Reulen RC, Toogood AA, et al. Health care use of long-term survivors of childhood cancer: the British Childhood Cancer Survivor Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(31):4181-8. doi: 10.1200/jco.2011.36.5619 [published Online First: 2011/09/29]
11. Shaw AK, Pogany L, Speechley KN, et al. Use of health care services by survivors of childhood and adolescent cancer in Canada. *Cancer* 2006;106(8):1829-37. doi: 10.1002/cncr.21798 [published Online First: 2006/03/17]



12. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Annals of family medicine* 2004;2(1):61-70. [published Online First: 2004/04/01]
13. Streefkerk N, Heins MJ, Teepen JC, et al. The involvement of primary care physicians in care for childhood cancer survivors. *Pediatric blood & cancer* 2019;66(8):e27774. doi: 10.1002/pbc.27774 [published Online First: 2019/04/30]
14. McBride ML, Lorenzi MF, Page J, et al. Patterns of physician follow-up among young cancer survivors: report of the Childhood, Adolescent, and Young Adult Cancer Survivors (CAYACS) research program. *Canadian family physician Medecin de famille canadien* 2011;57(12):e482-90. [published Online First: 2011/12/16]
15. Ahrensberg JM, Fenger-Gron M, Vedsted P. Use of primary care during the year before childhood cancer diagnosis: a nationwide population-based matched comparative study. *PLoS One* 2013;8(3):e59098. doi: 10.1371/journal.pone.0059098 [published Online First: 2013/04/05]
16. Yang TO, Liu YL, Huang WT, et al. Specific and Non-specific Clinical Presentations in the Year Before the Diagnosis of Childhood Leukaemia. *Pediatric blood & cancer* 2016;63(8):1387-93. doi: 10.1002/pbc.26029 [published Online First: 2016/04/30]
17. Ahrensberg JM, Fenger-Gron M, Vedsted P. Primary Care Use before Cancer Diagnosis in Adolescents and Young Adults - A Nationwide Register Study. *PLoS One* 2016;11(5):e0155933. doi: 10.1371/journal.pone.0155933 [published Online First: 2016/05/21]
18. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS medicine* 2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885 [published Online First: 2015/10/07]
19. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. *Leukemia* 2010;24(2):345-54. doi: 10.1038/leu.2009.251 [published Online First: 2009/12/17]
20. Gjerstorff ML. The Danish Cancer Registry. *Scandinavian journal of public health* 2011;39(7 Suppl):42-5. doi: 10.1177/1403494810393562 [published Online First: 2011/08/04]
21. Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service Register. *Scandinavian journal of public health* 2011;39(7 Suppl):34-7. doi: 10.1177/1403494810394718 [published Online First: 2011/08/04]
22. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scandinavian journal of public health* 2011;39(7 Suppl):30-3. doi: 10.1177/1403494811401482 [published Online First: 2011/08/04]
23. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. *European journal of epidemiology* 2014;29(8):541-9. doi: 10.1007/s10654-014-9930-3 [published Online First: 2014/06/27]
24. Erlangsen A, Fedyszyn I. Danish nationwide registers for public health and health-related research. *Scandinavian journal of public health* 2015;43(4):333-9. doi: 10.1177/1403494815575193 [published Online First: 2015/03/12]
25. Rasmussen LA, Jensen H, Virgilsen LF, et al. Healthcare utilisation in general practice and hospitals in the year preceding a diagnosis of cancer recurrence or second primary

1  
2  
3 cancer: a population-based register study. *BMC health services research* 2019;19(1):941.  
4 doi: 10.1186/s12913-019-4757-y [published Online First: 2019/12/07]  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



45 Flow diagram of the study population


46 Children with relapse/SMN and matched references in first remission.

47 \*Matching on age group, sex, risk group and treatment protocol.

48 †The number in brackets is the number of unique persons – the same child can serve as a control more than once.

49 Ph-negative BCR-ALL or T-ALL, Philadelphia chromosome-negative B-cell precursor or T-lineage acute lymphoblastic leukaemia; CPR number, civil personal registration number; HSCT in CR1, haematopoietic stem cell transplantation in first complete remission; SMN, second malignant neoplasm.

52 136x190mm (300 x 300 DPI)



### General practice health care utilisation

General practice utilisation by months before event for cases\* (n=60) compared with references† (n=295).

(A) Daytime. (B) Out-of-hours. (C) Diagnostic procedures.


Top panel: Contacts/diagnostic procedure mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, Second malignant neoplasm.

282x105mm (300 x 300 DPI)



#### Hospital health care utilization

Hospital health care utilisation by months before event for cases\* (n=60) compared with references† (n=295).


Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.

133x144mm (300 x 300 DPI)



Health care utilisation

Health care utilisation by months before event for cases (n=49) compared with references\* (n=243). Cases are survivors of childhood ALL developing a relapse as the first event (cases developing an SMN are excluded in this analysis).

Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.

265x146mm (300 x 300 DPI)

Table S1

The RECORD statement – checklist of items extended from the STROBE statement to be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
<b>Title and abstract</b>					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pages 1 and 2	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 2  Page 2  Page 2
<b>Introduction</b>					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Pages 3-4		
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4		
<b>Methods</b>					
Study Design	4	Present key elements of study design early in the paper	Page 4		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pages 4-5		
Participants	6	(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Page 5	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not	Page 5  N/A

1 2 3 4 5 6 7 8 9		<p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	Page 5	<p>published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	Figure 1	
10 11 12 13 14 15	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Pages 5-7	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Supplementary Table S2
16 17 18 19 20 21	Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Text box		
22 23	Bias	9	Describe any efforts to address potential sources of bias	Pages 10-11		
24 25	Study size	10	Explain how the study size was arrived at	Page 5		
26 27 28 29	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	N/A		
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed</p>	<p>Page 7</p> <p>Page 7</p> <p>N/A</p> <p>N/A</p>		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47



1		<i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy			
2		(e) Describe any sensitivity analyses			
3			Page 7		
4					
5					
6					
7	Data access and cleaning methods	..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Page 5
8				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	N/A
9					
10					
11					
12					
13					
14					
15	Linkage	..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Page 5
16					
17					
18					
19					
20					
21					
22	<b>Results</b>				
23	Participants	13	(a) Report the numbers of individuals at each stage of the study ( <i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	Figure 1  Figure 1  Figure 1	RECORD 13.1: Describe in detail the selection of the persons included in the study ( <i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.
24					Page 5 and Figure 1
25					
26					
27					
28					
29					
30					
31					
32					
33	Descriptive data	14	(a) Give characteristics of study participants ( <i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time ( <i>e.g.</i> , average and total amount)	Table 1  Table 1  Table 1	
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					

1 2 3 4 5 6 7 8 9	Outcome data	15	<p><i>Cohort study</i> - Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i> - Report numbers of outcome events or summary measures</p>	Page 8		
10 11 12 13 14 15 16 17 18 19 20	Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p>	<p>Pages 8-9 and Figures 2-3</p> <p>Table 1</p> <p>N/A</p>		
21 22 23	Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Page 9, Figure 4		
24	<b>Discussion</b>					
25 26	Key results	18	Summarise key results with reference to study objectives	Page 10		
27 28 29 30 31 32 33	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pages 10-11	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Pages 10-11
34 35 36 37 38	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 11		
39 40	Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11		
41	<b>Other Information</b>					
42 43 44 45 46 47	Funding	22	Give the source of funding and the role of the funders for the present study	Page 13		

		and, if applicable, for the original study on which the present article is based			
1					
2	Accessibility of protocol, raw data, and programming code	..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Page 14
3					
4					
5					
6					

\*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

\*Checklist is protected under Creative Commons Attribution ([CC BY](#)) license.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table S2.**

Information about contacts to general practice obtained from the Danish National Health Insurance Service Register

Contact type	Speciality code	Time code	Services
<b>Daytime contacts</b>	80	1	
			0101 0102 0105 0201 0411 0421 0431 0441 0451 0461 0491
<b>Out-of-hours contacts</b>	80	8 9	
			0101 0102 0471 0501
<b>Diagnostic procedures</b>	80	1 8 9	
Blood test			2101 2601 4309 4311 4312 4544 4611 7108 7110 7115 7120 7125 7126 7136 7150 7159 7168

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

			7177 7184 7186 7256 7263 7301 7302 7305 7309 7330 7403
Urine test			2132 4308 7101 7102 7122 7189
Strep throat test			4310 7109
Pulmonary functions test			4543 7113 7121 7183
Electrocardiogram			4313 7155 7156

For peer review only

# BMJ Open

## Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia: a population-based matched cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050285.R1
Article Type:	Original research
Date Submitted by the Author:	15-Jun-2021
Complete List of Authors:	Jensen, Karen; Aarhus University Hospital, Department of Paediatrics and Adolescent Medicine Klug Albertsen, Birgitte; Aarhus University Hospital, Department of Pediatrics and Adolescent Medicine Schrøder, Henrik; Aarhus University Hospital, Department of Paediatrics and Adolescent Medicine Zalounina Falborg, Alina; Aarhus University, Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health Schmiegelow, Kjeld; Copenhagen University Hospital, Department of Paediatrics and Adolescent Medicine; University of Copenhagen, Institute of Clinical Medicine, Faculty of Health and Medical Sciences Rosthøj, Steen ; Aalborg University Hospital, Department of Paediatrics and Adolescent Medicine Callesen, Michael Thude; Odense University Hospital, Hans Christian Andersen Children's Hospital Vedsted, Peter; Aarhus Universitet, Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health
<b>Primary Subject Heading</b>:	Haematology (incl blood transfusion)
Secondary Subject Heading:	General practice / Family practice, Paediatrics
Keywords:	Leukaemia < HAEMATOLOGY, Paediatric oncology < PAEDIATRICS, PRIMARY CARE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia: a population-based matched cohort study

Karen Schow Jensen<sup>1</sup>, Birgitte Klug Albertsen<sup>1</sup>, Henrik Schrøder<sup>1</sup>, Alina Zalounina Falborg<sup>2</sup>, Kjeld Schmiegelow<sup>3,4</sup>, Steen Rosthøj<sup>5</sup>, Michael Thude Callesen<sup>6</sup> and Peter Vedsted<sup>2</sup>

<sup>1</sup>Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.

<sup>2</sup>Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.

<sup>3</sup>Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark.

<sup>4</sup>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

<sup>5</sup>Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark.

<sup>6</sup>Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.



1  
2  
3  
4  
5  
6  
7 Corresponding author: Karen Schow Jensen, Department of Paediatrics and Adolescent Medicine,  
8  
9 Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus N, Denmark.

10  
11  
12 E-mail: [kascje@rm.dk](mailto:kascje@rm.dk)  
13  
14  
15

16  
17  
18 Abstract: 300 words  
19

20  
21 Main text: 2015 words, one text box, one table and four figures  
22

23  
24  
25 Supplementary data: Two tables  
26  
27

## 28 Abstract

29  
30  
31  
32

33 **Objectives** To investigate health care utilisation including both primary and secondary health care six  
34  
35 months before the diagnosis of a relapse or a second malignant neoplasm (SMN) in survivors of  
36  
37 childhood acute lymphoblastic leukaemia (ALL).  
38  
39  
40

41  
42 **Design and setting** A Danish population-based matched cohort study linking multiple nationwide  
43  
44 registries.  
45  
46

47  
48 **Participants** Participants was recruited from a total of 622 childhood ALL 2.5-year event-free  
49  
50 survivors diagnosed between 1994 and 2015. Cases were survivors developing a relapse or an  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 SMN and references were survivors still in first remission. Each case was matched with five  
4  
5  
6 references on age, sex, treatment protocol and risk group.  
7

8  
9 **Primary outcome measures** Consultations in general practice and hospital the last six months before  
10  
11 relapse or SMN. Cases and references were compared with monthly incidence rate ratios (IRR) from  
12  
13 negative binomial regression models.  
14  
15  
16

17  
18 **Results** Of the 622 childhood ALL survivors, 60 (9.6%) developed a relapse (49) or an SMN (11) and  
19  
20 295 matched references were identified. Health care utilisation in general practice increased among  
21  
22 cases the last month before the event compared with references with an IRR of 2.71 (95% CI 1.71-  
23  
24 4.28). Data showed a bimodal structure with a significantly increased number of visits four, five and  
25  
26 six months before the event. Hospital health care utilisation increased two months before the event  
27  
28 in cases with an IRR of 5.01 (3.78-6.63) the last month before the event and an IRR of 1.94 (1.32-  
29  
30 2.85) the second-last month comparing cases and references.  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **Conclusions** Survivors of childhood ALL developing a relapse or an SMN have a short period of  
41  
42 increased health care utilisation before diagnosis. At hospital, this might be explained by pre-  
43  
44 diagnostic examinations. In general practice, data suggest a bimodal structure with children later  
45  
46 developing a relapse having more contacts also half a year before the relapse, suggesting that there  
47  
48  
49 could be early warnings.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Keywords

Leukaemia, Paediatric oncology, Primary care

## Strengths and limitations of this study

- The first study to investigate healthcare utilisation before a relapse or an SMN in survivors of childhood ALL.
- Use of complete nationwide registries with nearly no loss to follow-up linked on an individual level ensured that the study was population-based thus limiting selection bias.
- Outcome data are collected routinely and uniformly in the Danish healthcare system and potential misclassification is thus expected to be non-differential.
- A small case group, leading to low statistical precision.
- Unmeasured confounding could be present.

## Introduction

Five-year survival from childhood acute lymphoblastic leukaemia (ALL) now exceeds 90% with an event-free five-year survival of around 85%.<sup>1</sup> With increased survival rates, more survivors need

1  
2  
3 scheduled surveillance programmes for detection of possible late effects as well as screening for  
4  
5  
6 relapse of ALL or second malignant neoplasm (SMN). ALL survivors are known to have more  
7  
8  
9 chronic conditions (late effects) than their general population peers and to have increased use of  
10  
11  
12 both primary and secondary health care services after end of treatment.<sup>2-14</sup> Studies examining the  
13  
14  
15 occurrence of late effects have contributed with important knowledge to follow-up programmes.  
16  
17  
18 However, to the best of our knowledge, no studies have investigated the use of health care before a  
19  
20  
21 relapse or an SMN in survivors of childhood ALL.  
22  
23  
24  
25  
26  
27

28 Studies of health care use before a primary diagnosis of childhood ALL have revealed increased  
29  
30  
31 health care use 2-3 months before the diagnosis, thus reflecting a short period of symptoms.<sup>15 16</sup>  
32  
33

34 Adolescents and young adults are found to have a longer interval with increased primary health care  
35  
36  
37 use for 5-6 months before primary diagnosis.<sup>17</sup> Earlier studies indicate that the increased primary  
38  
39  
40 health care use could have a bimodal structure with the first peak 10-12 months before the primary  
41  
42  
43 diagnosis.<sup>15</sup>  
44  
45  
46  
47  
48

49 Health care utilisation may reflect both the duration of symptoms before the diagnosis is established  
50  
51  
52 and the sectorial distribution of utilised care associated with these symptoms. Considerable focus is  
53  
54  
55 devoted to follow-up strategies for this group, and knowledge about the duration of increased health  
56  
57  
58  
59  
60

1  
2  
3 care use and the sectorial distribution of patients' help-seeking behaviour is therefore highly  
4  
5  
6 relevant. To address this knowledge gap, we aimed to analyse health care utilisation in general  
7  
8  
9 practice and hospital during the six-month period preceding a relapse or an SMN in survivors of  
10  
11  
12 childhood ALL.  
13

## 14 15 16 17 18 19 **Methods**

### 20 21 22 23 **Study design and setting**

24  
25  
26  
27 This study is a nationwide, population-based, matched cohort study linking information from several  
28  
29  
30 Danish registries. We followed the RECORD guidelines for reporting of studies conducted using  
31  
32  
33 observational, routinely collected health data.<sup>18</sup> (Supplementary Table S1).  
34  
35  
36  
37  
38  
39

40 In Denmark, the health care system is tax-financed and free and equally available to all residents  
41  
42  
43 (population 5.8 million). All children in Denmark developing ALL are treated in this tax-financed  
44  
45  
46 system ensuring that the study is population-based. After ALL treatment cessation, children in  
47  
48  
49 Denmark are followed in hospital-based outpatient surveillance programs; visits are scheduled 6-12  
50  
51  
52 times the first year, 4-6 times the second year and 1-3 times a year the following years.<sup>19</sup> There are  
53  
54  
55 no scheduled visits in general practice.  
56  
57  
58  
59  
60

1  
2  
3 All Danish citizens are assigned a unique identifier, the Civil Personal Registration (CPR) number.  
4  
5

6 The CPR number follows every resident from birth to death; data extracted from Danish public  
7  
8 registries were linked on an individual level using the CPR number.  
9  
10

## 11 12 13 14 15 16 Participants

17  
18  
19 Eligible subjects were patients (1.0-17.9 years) diagnosed with non-infant B-cell precursor or T-  
20  
21 lineage ALL between 1994 and 2015, and treated according to three consecutive Nordic Society of  
22  
23 Pediatric Hematology and Oncology (NOPHO) trials the ALL1992, ALL2000 and ALL2008 trials.<sup>1 20</sup>  
24  
25

26  
27  
28 Participants were identified in the Danish part of the NOPHO ALL registry. Cases were defined as  
29  
30 childhood ALL survivors having a relapse or an SMN as the first event 2.5 years or more after  
31  
32 primary diagnosis and before December 2017. Cases were matched 1:5 with childhood ALL  
33  
34 survivors still in first remission with the same sex, age group (under 10 years or 10 years or more),  
35  
36 NOPHO treatment protocol (ALL1992, ALL2000 or ALL2008) and risk group (high-risk or non-high  
37  
38 risk) (see flow chart, Figure 1). Matching was based on incidence density sampling using the STATA  
39  
40 command, sttocc. Due to the population-based design, the study sample size was determined by the  
41  
42 number of cases in the area during the study period and no sample size calculation was performed.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Data sources and variables

Data were extracted from national registries (Text box) and hosted by Statistics Denmark. Authors had access to a de-identified data output. Data on health care utilisation were extracted for the period 1 January 1997 to 31 December 2017. A relapse is defined as the reoccurrence of ALL after complete remission; a relapse can occur as an isolated bone marrow relapse, an isolated extramedullary relapse (e.g. the central nervous system or testis) or a combined bone marrow and extramedullary relapse. SMN is defined as the occurrence of a new malignant neoplasm. Survivors of ALL are at increased risk of developing a new malignant neoplasm compared to population peers; other haematological malignancies and tumours of the central nerves system are the most common types of SMNs.<sup>21</sup>

### Text box. Data sources and variables

	Registries	Variables
<b>Exposures</b>	NOPHO ALL Registry* <sup>1</sup> <sup>20</sup>	Relapse of ALL
		First remission
	Danish Cancer Registry† <sup>22</sup>	Second malignant neoplasm
<b>Outcomes</b>		
Primary health care	National Health Insurance	Daytime contacts to general practice:
	Service Register‡ <sup>23</sup>	Daytime face-to-face contacts

		Email consultations
		Daytime telephone consultations
		Daytime home visits
		Out-of-hours contacts:
		Out-of-hours face-to-face contacts
		Out-of-hours telephone consultations
		Out-of-hours home visits
		Diagnostic procedures in general practice:
		Blood test
		Urine test
		Streptococcus throat test
		Pulmonary functions test
		Electrocardiogram
Secondary health care	Danish National Patient Registry <sup>24</sup>	Contacts to public and private hospitals: Inpatient hospitalisations Outpatient visits
<b>Covariates</b>	Danish Civil Registration System <sup>25</sup>	Sex Age Vital status Immigration Emigration
	NOPHO ALL Registry	Diagnosis of childhood ALL



---

Treatment protocol (ALL1992, ALL2000 or  
ALL2008)  
Risk group (high-risk or non-high risk)  
Immunophenotype (B-precursor ALL or T-  
ALL)

---

\*NOPHO ALL Registry, Nordic Society of Paediatric Haematology and Oncology ALL Registry. The registry holds data on all children aged 1.0-14.9 years in Denmark diagnosed with ALL since 1992. From 2008 and onwards, the ALL Registry was extended to include children and adolescents aged 1.0-17.9 years.

†The Danish Cancer Registry holds information on all new cases of cancer in Denmark.

‡The National Health Insurance Service Register holds information on all contacts to general practice in Denmark. The following contacts were excluded: preventive health examination of children, vaccinations, screening for cervical cancer and pregnancy care. For a complete list of codes, see Supplementary data Table S2.

§The Danish National Patient Registry holds information on all contacts to public and private hospitals. The following contacts were excluded: visits to the accident and emergency department.

## Statistical methods

The index date was the date of event (relapse or SMN) for cases. The corresponding index date for references was defined as the date with the same interval from the primary diagnosis as for the case. For all included individuals, follow-up started no earlier than 2.5 years after diagnosis to ensure that treatment had ended and remission reached. Health care utilisation was assessed from six months before the index date/event.

1  
2  
3 The monthly rates for primary health care contacts (daytime contacts, out-of-hours contacts and  
4  
5  
6 diagnostic procedures) and hospital contacts (inpatient hospitalisations and hospital outpatient  
7  
8  
9 contact) were calculated as crude estimates for each of the six months preceding the index date.

10  
11  
12 Negative binominal regression models were used to calculate incidence rate ratios (IRRs) to  
13  
14  
15 compare monthly rates of contacts between cases and references. Cluster robust variance  
16  
17  
18 estimation was applied to account for possible cluster effects at patient level. This was relevant as  
19  
20  
21 measurements on the same person were repeated monthly.  
22  
23  
24  
25  
26  
27

28 Estimates of IRRs were adjusted for sex, age and time since diagnosis. To adjust for age and time  
29  
30 since diagnosis, we used restricted cubic splines with six knots to allow for a non-linear relationship.  
31  
32  
33

34 Furthermore, we performed analyses restricted to cases developing a relapse and to their  
35  
36 references. All estimates are presented with 95% confidence intervals (CIs). All tests were two-sided  
37  
38  
39 and a P-value  $\leq 0.05$  was considered statistically significant. Data were analysed using the statistical  
40  
41  
42 software Stata 16.1 (StataCorp LLC, TX, USA).  
43  
44  
45  
46  
47  
48

## 49 Patient and public involvement

50  
51  
52  
53 The study included no patient and public involvement.  
54  
55  
56  
57  
58  
59  
60

## Results

### Patient characteristics

The study included 60 cases and 295 references; 49 (81.7%) of the 60 cases suffered a relapse and 11 (18.3%) an SMN (Table 1). In two cases, there were fewer than five matching references.

Table 1. Characteristics of the study population

Characteristic	Cases* N = 60	References† N = 295
Sex, n (%)		
Male	38 (63.3)	190 (64.4)
Female	22 (36.7)	105 (35.6)
Median age at index date‡, (IQR)	11.3 (8.4-16.1)	11.1 (7.7-15.7)
Age group at index date, n (%)		
Age < 10 years	21 (35.0)	130 (44.1)
Age ≥ 10 years	39 (65.0)	165 (55.9)
Treatment protocol, n (%)		
NOPHO ALL1992	24 (40.0)	120 (40.7)
NOPHO ALL2000	22 (36.7)	105 (35.6)
NOPHO ALL2008	14 (23.3)	70 (23.7)

Cell line, n (%)		
B-precursor ALL	55 (91.7)	253 (85.8)
T-ALL	5 (8.3)	42 (14.2)
Risk group, n (%)		
Non-high-risk	46 (76.7)	230 (78.0)
High-risk	14 (23.3)	65 (22.0)
Median time from diagnosis to index date (years, IQI)	3.8 (3.2-5.1)	3.8 (3.2-5.1)
Type of event, n (%)		
Relapse	49 (81.7)	-
SMN	11 (18.3)	-

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

‡Index date, the date of event for cases and the corresponding date for references.

SMN, second malignant neoplasm; IQI, interquartile interval; NOPHO, Nordic Society of Paediatric Haematology and Oncology; ALL, acute lymphoblastic leukaemia.

## Health care utilisation

We found a mean of 0.73 (95% CI: 0.53-1.02) daytime general practice visits during the month before the event in cases corresponding to an IRR of 2.71 (95% CI: 1.71-4.28). For the month before the event, we found an IRR of 8.12 (95% CI 3.01-21.86) for general practice out-of-hours contacts and an IRR of 5.89 (95% CI 2.44-14.21) for diagnostic procedures in general practice (Figure 2). For

1  
2  
3 daytime general practice visits, data suggest a possible bimodal structure with increased IRRs  
4  
5  
6 during 4-6 months before the event.  
7  
8  
9

10  
11  
12 For cases, hospital utilisation was 3.42 (95% CI 2.83-4.12) contacts in the last month before the  
13  
14  
15 event compared to 0.72 (95% CI 0.61-0.85) contacts for references, corresponding to an IRR of 5.01  
16  
17  
18 (95% CI 3.78-6.63) the month before the event. For the second-last month before the event, we  
19  
20  
21 found an IRR of 1.94 (95% CI 1.32-2.85) (Figure 3).  
22  
23  
24  
25  
26  
27

28 In analyses restricted to cases developing a relapse, hospital utilisation also increased two months  
29  
30  
31 before the event (significantly increased only one month before the event). In general practice, data  
32  
33  
34 continued to suggest a bimodal structure (Figure 4).  
35  
36  
37  
38  
39

## 40 Discussion

41  
42  
43  
44

45 The present national, population-based matched cohort study shows that utilisation of general  
46  
47  
48 practice and hospital services increased significantly two months before the diagnosis of a relapse or  
49  
50  
51 an SMN compared to references still in first remission. Our data showed a bimodal structure for  
52  
53  
54 daytime consultations in general practice in general and for cases developing a relapse more  
55  
56  
57  
58  
59  
60

1  
2  
3 pronounced, with increased utilisation 5-6 months before relapse. This indicates that there could be  
4  
5  
6 early warnings. The increased use of hospital health care services the last month before relapse is  
7  
8  
9 most likely explained by the diagnostic workup.  
10

## 11 12 13 14 15 16 Strengths and limitations

17  
18  
19 The population-based design with use of nationwide registries linked on an individual level is a  
20  
21  
22 strength. This ensured optimal completeness of data and follow-up. However, a relapse diagnosis is  
23  
24  
25 not registered in the Danish Cancer Registry. Therefore, data on relapses were collected from the  
26  
27  
28 NOPHO ALL registry.<sup>1 20</sup> The NOPHO ALL registry is a very robust data source as it is updated  
29  
30  
31 regularly by research nurses and paediatric oncologists. Nevertheless, the registry might not contain  
32  
33  
34 data on all relapses that occur after patients leave a paediatric department. Children with a relapse  
35  
36  
37 that was unregistered would belong to the reference group, which could lead to bias towards  
38  
39  
40 underestimating relapse frequency and the differences in use of health care services.  
41  
42  
43  
44  
45  
46

47 Electronic outcome data are collected routinely and uniformly in the Danish healthcare system. Data  
48  
49  
50 were collected for remuneration and not for the purpose of the present study. Potential  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 misclassification of outcomes is expected to be equally distributed among cases and references, and  
4  
5  
6 any such misclassification is expected to be non-differential.<sup>26</sup>  
7  
8  
9

10  
11  
12 The relatively small case group in our study is a limitation, leading to a low statistical precision with  
13  
14  
15 broad confidence intervals. Another limitation is the absence of information regarding the motivations  
16  
17  
18 for contacts to the healthcare system as this information is not available in the National Health  
19  
20  
21 Insurance Service Register.<sup>23</sup>  
22  
23  
24  
25  
26  
27

28 We compared periods with the same interval from diagnosis in cases and references as previous  
29  
30  
31 research has shown that time since diagnosis affects utilisation of health care.<sup>2 5 8 9</sup> We made an  
32  
33  
34 effort to reduce confounding by age, gender, calendar period and treatment regime by matching  
35  
36  
37 cases with references. We had no information on the amount and type of late effects and we were  
38  
39  
40 thus not able to match by late effects. However, previous studies suggest that the types of late  
41  
42  
43 effects have changed over calendar time making it relevant to match on treatment era (protocol).<sup>6</sup>  
44  
45

46 We were not able to adjust for sociodemographic factors and unmeasured confounding could thus  
47  
48  
49 be present. We expect potential bias to be negligible, and we believe that our findings can be  
50  
51  
52 generalised to other countries with comparable healthcare systems.  
53  
54  
55  
56  
57  
58  
59  
60

## Comparison with existing literature

Previous studies on health care utilisation in ALL survivors have found increased use of primary and secondary health care after end of treatment.<sup>2-14</sup> However, previous studies did not evaluate health care use before a relapse or an SMN. Studies on health care utilisation before primary ALL diagnosis in childhood found increased use of health care 2-3 months before the primary diagnosis;<sup>15 16</sup> and based on these findings, we expected a short duration of increased health care use. Furthermore, a bimodal structure for general practice health care use before the primary diagnosis is reported, but with the first peak 10-12 months before diagnosis.<sup>15</sup>

A recent study examining use of health care before a cancer recurrence or an SMN in adult cancer survivors reported increased use of health care up to a year before diagnosis among patients diagnosed with a wide range of solid tumours.<sup>27</sup> Based on knowledge on health care use before a primary cancer, it is expected that patients with solid tumours have a longer interval of increased health care utilisation.<sup>15 17</sup>

## Conclusions

Survivors of childhood ALL developing a relapse or an SMN when in remission had a higher use of general practice and hospital health care services compared with matched references, 1-2 months



1  
2  
3 before the event. There was a possible bimodal structure for daytime visits to general practice with  
4  
5  
6 increased visits also 4-6 months before the event. As health care utilisation may be seen as a proxy  
7  
8  
9 for morbidity, this indicates that there could be early warnings. To the best of our knowledge, this is  
10  
11  
12 the first study to investigate use of health care before a relapse or an SMN in survivors of childhood  
13  
14  
15 ALL in remission, and further research is needed. If an increased use of general practice services up  
16  
17  
18 to 6 months before the diagnosis of a relapse or an SMN is confirmed in future research, there may  
19  
20  
21 be a window for earlier diagnosis. An increased knowledge of the patient pathway to relapse/SMN  
22  
23  
24 diagnosis is important to ensure optimal organisation of surveillance programmes.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 Figure legends

### 40 41 42 43 Figure 1 Flow diagram of the study population

44  
45  
46 Children with relapse/SMN and matched references in first remission.

47 \*Matching on age group, sex, risk group and treatment protocol.

48 †The number in brackets is the number of unique persons – the same child can serve as a control  
49 more than once and controls can later become cases.

50  
51  
52 BCR-ALL or T-ALL, B-cell precursor or T-lineage acute lymphoblastic leukaemia; CPR number, civil  
53 personal registration number; HSCT in CR1, haematopoietic stem cell transplantation in first  
54 complete remission; SMN, second malignant neoplasm.  
55  
56  
57  
58  
59  
60

## Figure 2 General practice health care utilisation

General practice utilisation by months before event for cases\* (n=60) compared with references† (n=295). (A) Daytime. (B) Out-of-hours. (C) Diagnostic procedures.

Top panel: Contacts/diagnostic procedure mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, Second malignant neoplasm.

## Figure 3 Hospital health care utilization

Hospital health care utilisation by months before event for cases\* (n=60) compared with references† (n=295).

Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.

## Figure 4 Health care utilisation

Health care utilisation by months before event for cases (n=49) compared with references\* (n=243). Cases are survivors of childhood ALL developing a relapse as the first event (cases developing an SMN are excluded in this analysis).

Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

1  
2  
3 \*References, survivors of childhood ALL still in first remission matched on age, sex, treatment  
4 protocol and risk group.  
5

6 ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.  
7  
8  
9  
10  
11

## 12 Acknowledgments

13  
14  
15  
16

17 The authors wish to thank Kaare Rud Flarup for his assistance with data management.  
18  
19  
20  
21  
22  
23

## 24 Footnotes

25  
26  
27  
28

29 **Contributors:** KJ designed the study, analysed and interpreted data and wrote the manuscript; BA  
30  
31 interpreted data and edited the manuscript; HS designed the study and edited the manuscript; AF  
32  
33 analysed and interpreted data and edited the manuscript; KS interpreted data and edited the  
34  
35 manuscript; SR interpreted data and edited the manuscript; MC interpreted data and edited the  
36  
37 manuscript; PV designed the study, interpreted data and edited the manuscript. All authors approved  
38  
39  
40  
41 the final manuscript.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Funding:** This work was supported by a grant from the Danish Cancer Society (Kræftens  
4  
5  
6 Bekæmpelse). Grant number R124-A7831-15-S2. The funders had no role in the design and  
7  
8  
9 conduct of the study.  
10

11  
12  
13  
14  
15 **Competing interests:** Birgitte Klug Albertsen declares the following: sponsor for the investigator  
16  
17 initiated NOR-GRASPALL 2016 study. Kjeld Schmiegelow declares the following: Speaker and/or  
18  
19 Advisory Board Honoraria from Jazz Pharmaceuticals (2020) and Servier (2020); speaker fee from  
20  
21 Amgen (2020) and Medscape (2020); Educational grant from Servier (2020). The remaining authors  
22  
23  
24  
25 declare that they have no competing interests.  
26  
27  
28  
29  
30  
31  
32  
33

34 **Patient consent for publication:** Not required.  
35  
36  
37  
38  
39

40 **Ethical approval:** This study was approved by the Danish Data Protection Agency (ID 277). Medical  
41  
42  
43 ethical approval was not required according to Danish law.  
44  
45  
46  
47  
48


49 **Data sharing statement:** According to the data agreement with the data provider, we are not allowed  
50  
51  
52 to share our data. Data are stored and maintained electronically at Statistics Denmark.  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. *Leukemia* 2018;32(3):606-15. doi: 10.1038/leu.2017.265 [published Online First: 2017/08/19]
2. de Fine Licht S, Rugbjerg K, Gudmundsdottir T, et al. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors. *PLoS medicine* 2017;14(5):e1002296. doi: 10.1371/journal.pmed.1002296 [published Online First: 2017/05/10]
3. Font-Gonzalez A, Feijen E, Geskus RB, et al. Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage study. *Cancer medicine* 2017;6(5):1123-34. doi: 10.1002/cam4.1057 [published Online First: 2017/04/06]
4. Sieswerda E, Font-Gonzalez A, Reitsma JB, et al. High Hospitalization Rates in Survivors of Childhood Cancer: A Longitudinal Follow-Up Study Using Medical Record Linkage. *PLoS One* 2016;11(7):e0159518. doi: 10.1371/journal.pone.0159518 [published Online First: 2016/07/21]
5. Sorensen GV, Winther JF, de Fine Licht S, et al. Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries. *Journal of the National Cancer Institute* 2019;111(9):943-51. doi: 10.1093/jnci/djz016 [published Online First: 2019/02/13]
6. Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. *The Lancet Haematology* 2019;6(6):e306-e16. doi: 10.1016/s2352-3026(19)30050-x [published Online First: 2019/05/13]
7. Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet (London, England)* 2017;390(10112):2569-82. doi: 10.1016/s0140-6736(17)31610-0 [published Online First: 2017/09/12]
8. Heins MJ, Lorenzi MF, Korevaar JC, et al. Non-oncology physician visits after diagnosis of cancer in adolescents and young adults. *Journal of cancer survivorship : research and practice* 2016;10(4):783-8. doi: 10.1007/s11764-016-0523-x [published Online First: 2016/02/15]
9. Heins MJ, Lorenzi MF, Korevaar JC, et al. Non-oncology physician visits after diagnosis of cancer in children. *BMC family practice* 2016;17:60. doi: 10.1186/s12875-016-0462-7 [published Online First: 2016/06/02]
10. Rebholz CE, Reulen RC, Toogood AA, et al. Health care use of long-term survivors of childhood cancer: the British Childhood Cancer Survivor Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(31):4181-8. doi: 10.1200/jco.2011.36.5619 [published Online First: 2011/09/29]
11. Shaw AK, Pogany L, Speechley KN, et al. Use of health care services by survivors of childhood and adolescent cancer in Canada. *Cancer* 2006;106(8):1829-37. doi: 10.1002/cncr.21798 [published Online First: 2006/03/17]

12. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Annals of family medicine* 2004;2(1):61-70. [published Online First: 2004/04/01]
13. Streefkerk N, Heins MJ, Teepen JC, et al. The involvement of primary care physicians in care for childhood cancer survivors. *Pediatric blood & cancer* 2019;66(8):e27774. doi: 10.1002/pbc.27774 [published Online First: 2019/04/30]
14. McBride ML, Lorenzi MF, Page J, et al. Patterns of physician follow-up among young cancer survivors: report of the Childhood, Adolescent, and Young Adult Cancer Survivors (CAYACS) research program. *Canadian family physician Medecin de famille canadien* 2011;57(12):e482-90. [published Online First: 2011/12/16]
15. Ahrensberg JM, Fenger-Gron M, Vedsted P. Use of primary care during the year before childhood cancer diagnosis: a nationwide population-based matched comparative study. *PLoS One* 2013;8(3):e59098. doi: 10.1371/journal.pone.0059098 [published Online First: 2013/04/05]
16. Yang TO, Liu YL, Huang WT, et al. Specific and Non-specific Clinical Presentations in the Year Before the Diagnosis of Childhood Leukaemia. *Pediatric blood & cancer* 2016;63(8):1387-93. doi: 10.1002/pbc.26029 [published Online First: 2016/04/30]
17. Ahrensberg JM, Fenger-Gron M, Vedsted P. Primary Care Use before Cancer Diagnosis in Adolescents and Young Adults - A Nationwide Register Study. *PLoS One* 2016;11(5):e0155933. doi: 10.1371/journal.pone.0155933 [published Online First: 2016/05/21]
18. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS medicine* 2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885 [published Online First: 2015/10/07]
19. Jensen KS, Oskarsson T, Lähteenmäki PM, et al. Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study. *Br J Haematol* 2021 doi: 10.1111/bjh.17555 [published Online First: 2021/05/28]
20. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. *Leukemia* 2010;24(2):345-54. doi: 10.1038/leu.2009.251 [published Online First: 2009/12/17]
21. Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(19):2469-76. doi: 10.1200/jco.2012.47.0500 [published Online First: 2013/05/22]
22. Gjerstorff ML. The Danish Cancer Registry. *Scandinavian journal of public health* 2011;39(7 Suppl):42-5. doi: 10.1177/1403494810393562 [published Online First: 2011/08/04]
23. Andersen JS, Olivarius Nde F, Krasnik A. The Danish National Health Service Register. *Scandinavian journal of public health* 2011;39(7 Suppl):34-7. doi: 10.1177/1403494810394718 [published Online First: 2011/08/04]
24. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scandinavian journal of public health* 2011;39(7 Suppl):30-3. doi: 10.1177/1403494811401482 [published Online First: 2011/08/04]

- 1  
2  
3 25. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in  
4 epidemiology. *European journal of epidemiology* 2014;29(8):541-9. doi:  
5 10.1007/s10654-014-9930-3 [published Online First: 2014/06/27]  
6  
7 26. Erlangsen A, Fedyszyn I. Danish nationwide registers for public health and health-related  
8 research. *Scandinavian journal of public health* 2015;43(4):333-9. doi:  
9 10.1177/1403494815575193 [published Online First: 2015/03/12]  
10  
11 27. Rasmussen LA, Jensen H, Virgilsen LF, et al. Healthcare utilisation in general practice and  
12 hospitals in the year preceding a diagnosis of cancer recurrence or second primary  
13 cancer: a population-based register study. *BMC health services research* 2019;19(1):941.  
14 doi: 10.1186/s12913-019-4757-y [published Online First: 2019/12/07]  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



45 Figure 1 Flow diagram of the study population  
46 Children with relapse/SMN and matched references in first remission.


47 \*Matching on age group, sex, risk group and treatment protocol.

48 †The number in brackets is the number of unique persons – the same child can serve as a control more than  
49 once and controls can later become cases.

50 BCR-ALL or T-ALL, B-cell precursor or T-lineage acute lymphoblastic leukaemia; CPR number, civil personal  
51 registration number; HSCT in CR1, haematopoietic stem cell transplantation in first complete remission;  
52 SMN, second malignant neoplasm.

53 209x297mm (300 x 300 DPI)





### General practice health care utilisation

General practice utilisation by months before event for cases\* (n=60) compared with references† (n=295).

(A) Daytime. (B) Out-of-hours. (C) Diagnostic procedures.


Top panel: Contacts/diagnostic procedure mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, Second malignant neoplasm.

282x105mm (300 x 300 DPI)



Hospital health care utilization

Hospital health care utilisation by months before event for cases\* (n=60) compared with references† (n=295).


Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*Cases, survivors of childhood ALL developing a relapse or an SMN as the first event.

†References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.

133x144mm (300 x 300 DPI)



#### Health care utilisation

Health care utilisation by months before event for cases (n=49) compared with references\* (n=243). Cases are survivors of childhood ALL developing a relapse as the first event (cases developing an SMN are excluded in this analysis).

Top panel: Contacts mean rates per month presented as crude rates. Bottom panel: Incidence rate ratios adjusted for age, sex and time since diagnosis. Vertical lines represent 95% confidence intervals.

\*References, survivors of childhood ALL still in first remission matched on age, sex, treatment protocol and risk group.

ALL, acute lymphoblastic leukaemia; SMN, second malignant neoplasm.

265x146mm (300 x 300 DPI)

Table S1

The RECORD statement – checklist of items extended from the STROBE statement to be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
<b>Title and abstract</b>					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pages 1 and 2	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 2  Page 2  Page 2
<b>Introduction</b>					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Pages 3-4		
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4		
<b>Methods</b>					
Study Design	4	Present key elements of study design early in the paper	Page 4		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pages 4-5		
Participants	6	(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Page 5	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not	Page 5  N/A

1 2 3 4 5 6 7 8 9		<p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	Page 5	<p>published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	Figure 1
10 11 12 13 14 15	Variables	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Pages 5-7	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Supplementary Table S2
16 17 18 19 20 21	Data sources/ measurement	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Text box		
22 23	Bias	Describe any efforts to address potential sources of bias	Pages 10-11		
24 25	Study size	Explain how the study size was arrived at	Page 5		
26 27 28 29	Quantitative variables	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	N/A		
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	Statistical methods	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed</p>	<p>Pages 7-8</p> <p>Page 8</p> <p>N/A</p> <p>N/A</p>		

		<i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Page 8		
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Page 5  N/A
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Page 5
<b>Results</b>					
Participants	13	(a) Report the numbers of individuals at each stage of the study ( <i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	Figure 1  Figure 1  Figure 1	RECORD 13.1: Describe in detail the selection of the persons included in the study ( <i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Page 5 and Figure 1
Descriptive data	14	(a) Give characteristics of study participants ( <i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time ( <i>e.g.</i> , average and total amount)	Table 1  Table 1  Table 1		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure	Page 8-10		

		<i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Pages 8-10 and Figures 2-3  Table 1  N/A		
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Page 10, Figure 4		
<b>Discussion</b>					
Key results	18	Summarise key results with reference to study objectives	Page 10		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pages 10-11	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Pages 10-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 12		
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11		
<b>Other Information</b>					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 14		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Page 15

1 \*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies  
2 Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.  
3

4 \*Checklist is protected under Creative Commons Attribution ([CC BY](#)) license.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only



**Table S2.**  
Information about contacts to general practice obtained from the Danish National Health Insurance Service Register

Contact type	Speciality code	Time code	Services
<b>Daytime contacts</b>	80	1	
			0101 0102 0105 0201 0411 0421 0431 0441 0451 0461 0491
<b>Out-of-hours contacts</b>	80	8 9	
			0101 0102 0471 0501
<b>Diagnostic procedures</b>	80	1 8 9	
Blood test			2101 2601 4309 4311 4312 4544 4611 7108 7110 7115 7120 7125 7126 7136 7150 7159 7168

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

			7177 7184 7186 7256 7263 7301 7302 7305 7309 7330 7403
Urine test			2132 4308 7101 7102 7122 7189
Strep throat test			4310 7109
Pulmonary functions test			4543 7113 7121 7183
Electrocardiogram			4313 7155 7156

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47